Regenerative Medical Technology (RMTG) Non-Current Assets (2018 - 2026)
Regenerative Medical Technology (RMTG) posted quarterly Non-Current Assets of $3.4 million for Q1 2026, up 36.05% year-over-year from $2.5 million in Q1 2025, and up 5.45% quarter-over-quarter from $3.3 million in Q4 2025.
Regenerative Medical Technology (RMTG) Non-Current Assets (2018 - 2026) Analysis & Trends
Regenerative Medical Technology's Non-Current Assets history runs 9 years deep, the most recent figure standing at $3.4 million for Q1 2026.
- In Q1 2026, Non-Current Assets rose 36.05% year-over-year to $3.4 million; the TTM figure through Mar 2026 stood at $12.3 million (up 25.72% YoY), while the FY2025 annual figure was $3.3 million, up 26.92% from the prior year.
- Non-Current Assets for Q1 2026 stood at $3.4 million, up from $3.3 million in the prior quarter.
- The five-year high for Non-Current Assets was $6.4 million in Q2 2022, with the low at $2.1 million in Q3 2023.
- The 5-year median for Non-Current Assets is $3.0 million (2025), against an average of $3.9 million.
- The sharpest annual moves came in 2022 and 2023: Non-Current Assets surged 3532.42% in 2022, then tumbled 66.67% in 2023.
- Regenerative Medical Technology's Non-Current Assets stood at $6.4 million in 2022, then plunged by 63.92% to $2.3 million in 2023, then increased by 11.68% to $2.6 million in 2024, then rose by 26.92% to $3.3 million in 2025, then advanced by 5.45% to $3.4 million in 2026.
- Business Quant data shows RMTG's Non-Current Assets at $3.4 million in Q1 2026, $3.3 million in Q4 2025, and $3.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 938.60 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 6.80 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 468.65 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 18.06 Bn |
| 10 | Regenerative Medical Technology | 1.58 Mn | 515,228.12 | 1.77 Mn | 3.44 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.44 Mn |
| Dec 31, 2025 | 3.27 Mn |
| Sep 30, 2025 | 3.01 Mn |
| Jun 30, 2025 | 2.58 Mn |
| Mar 31, 2025 | 2.53 Mn |
| Dec 31, 2024 | 2.57 Mn |
| Sep 30, 2024 | 2.31 Mn |
| Jun 30, 2024 | 2.36 Mn |
| Mar 31, 2024 | 2.41 Mn |
| Dec 31, 2023 | 2.30 Mn |
| Sep 30, 2023 | 2.13 Mn |
| Jun 30, 2023 | 6.27 Mn |
| Mar 31, 2023 | 6.33 Mn |
| Dec 31, 2022 | 6.39 Mn |
| Sep 30, 2022 | 6.38 Mn |
| Jun 30, 2022 | 6.42 Mn |
| Mar 31, 2022 | 6.31 Mn |
| Dec 31, 2021 | 6.29 Mn |
| Sep 30, 2021 | 6.29 Mn |
| Jun 30, 2021 | 176,800.00 |